Mild To Moderate Erectile Dysfunction Study
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Parallel Study of Men With Mild to Moderate Erectile Dysfunction to Evaluate the Efficacy of Viagra 8 Hours Post-Dose
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States
- Pfizer Investigational Site
-
Homewood, Alabama, United States
- Pfizer Investigational Site
-
Hoover, Alabama, United States
- Pfizer Investigational Site
-
Huntsville, Alabama, United States
- Pfizer Investigational Site
-
-
Arizona
-
Phoenix, Arizona, United States
- Pfizer Investigational Site
-
-
California
-
Beverly Hills, California, United States
- Pfizer Investigational Site
-
La Mesa, California, United States
- Pfizer Investigational Site
-
Newport Beach, California, United States
- Pfizer Investigational Site
-
San Diego, California, United States
- Pfizer Investigational Site
-
-
Colorado
-
Aurora, Colorado, United States
- Pfizer Investigational Site
-
-
Connecticut
-
Middlebury, Connecticut, United States
- Pfizer Investigational Site
-
Waterbury, Connecticut, United States
- Pfizer Investigational Site
-
-
Florida
-
Gainesville, Florida, United States
- Pfizer Investigational Site
-
New Port Richey, Florida, United States
- Pfizer Investigational Site
-
South Miami, Florida, United States
- Pfizer Investigational Site
-
Tallahassee, Florida, United States
- Pfizer Investigational Site
-
Tampa, Florida, United States
- Pfizer Investigational Site
-
-
Indiana
-
Fort Wayne, Indiana, United States
- Pfizer Investigational Site
-
Jeffersonville, Indiana, United States
- Pfizer Investigational Site
-
-
Iowa
-
Des Moines, Iowa, United States
- Pfizer Investigational Site
-
-
Louisiana
-
New Orleans, Louisiana, United States
- Pfizer Investigational Site
-
Shreveport, Louisiana, United States
- Pfizer Investigational Site
-
-
Mississippi
-
Hattiesburg, Mississippi, United States
- Pfizer Investigational Site
-
-
Nevada
-
Las Vegas, Nevada, United States
- Pfizer Investigational Site
-
-
New York
-
Bay Shore, New York, United States
- Pfizer Investigational Site
-
Kingston, New York, United States
- Pfizer Investigational Site
-
New York, New York, United States
- Pfizer Investigational Site
-
Poughkeepsie, New York, United States
- Pfizer Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, United States
- Pfizer Investigational Site
-
-
Tennessee
-
Nashville, Tennessee, United States
- Pfizer Investigational Site
-
-
Texas
-
San Antonio, Texas, United States
- Pfizer Investigational Site
-
-
Washington
-
Lacey, Washington, United States
- Pfizer Investigational Site
-
Spokane, Washington, United States
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men 18-70 years of age
- Documented clinical diagnosis of erectile dysfunction of at least 3 months duration.
Exclusion Criteria:
- Subjects with penile implants
- Subjects with a known history of retinitis pigmentosa.
- Subjects, due to the requirement of 100 mg dosage, who are receiving concomitant treatment with the potent CYP3A4 inhibitor ritonavir.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
To determine the proportion of sexual intercourses that are successful in men with mild to moderate ED 8 hrs after a dose of Viagra.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
To determine the proportion of sexual intercourses that are successful in men with mild to moderate ED 12 hrs after a dose of Viagra. Other questionnaires such as SEP, IIEF.
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- A1481230
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.